COLLABORATIVE ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES SCIENCE AWARD 
(CAMSSA)

RELEASE DATE:  October 2, 2003

PA NUMBER:  PAR-04-003

EXPIRATION DATE: October 1, 2006, unless reissued.

Department of Health and Human Services (DHHS)

PARTICIPATING ORGANIZATIONS: 

National Institutes of Health (NIH) 
 (http://www.nih.gov/)

COMPONENTS OF PARTICIPATING ORGANIZATIONS: 

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 
 (http://www.niams.nih.gov/)

CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER: 93.846

THIS PA CONTAINS THE FOLLOWING INFORMATION

o Purpose of the PA
o Research Objectives
o Mechanism(s) of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations

PURPOSE OF THIS PA

The objective of the Collaborative Arthritis and Musculoskeletal and Skin 
Diseases Science Award (CAMSSA) program is to develop and promote competitive 
scientific research programs in areas within the mission of the National 
Institute of Arthritis and Musculoskeletal and Skin Diseases at institutions 
with substantial minority enrollment.  The CAMSSA program is designed to 
encourage collaborative investigations among scientists at institutions with 
substantial minority enrollment with grantees from research-intensive 
institutions who have grant support to conduct research in arthritis, 
musculoskeletal diseases or skin diseases.  The nature of the collaborations 
will include joint research efforts, specialized training in research 
techniques, and participation in research seminars. The CAMSSA program should 
develop and expand scientific opportunities among the participating 
institutions for research in arthritis, musculoskeletal diseases or skin 
diseases. 

RESEARCH OBJECTIVES

o Characteristics of the CAMSSA Program: The CAMSSA will support an 
investigator-initiated research project in which the applicant and a 
collaborating scientist will work in a clearly defined area of mutual research 
interest related to arthritis, musculoskeletal diseases or skin diseases. 
Responsibility for the planning, direction, and execution of the proposed 
project will be solely that of the applicant and the collaborator.   Since the 
intent of the award is to develop competitive research programs at 
institutions with substantial minority enrollment, the applicant and 
collaborating investigators must document the potential for developing 
scientific approaches to accomplish the objectives of the proposed research 
project.  The project must consist of a scientifically meritorious research 
plan that involves an efficacious collaborative effort among the participating 
investigators, each of whom will be conducting a portion of the total research 
project in his/her own laboratory.  Examples of the collaborative interactions 
include the sharing of ideas, data, and exchanging of research techniques and 
expertise. It is anticipated that collaboration between the institutions will 
provide training opportunities for pre- and postdoctoral fellows at both 
institutions.  

o Consortium arrangement between the applicant institution with substantial 
minority enrollment and the collaborating research-intensive institution:  
Each of these institutions must provide the appropriate facilities and 
resources for the applicant and collaborating investigators to accomplish the 
goals of the proposed research program.  The CAMSSA requires effective 
research collaboration among these investigators, who must be full-time 
employees of their respective institutions.  These investigators must provide 
a detailed description of the nature and the extent of the research 
collaboration such that the necessary administrative and fiscal considerations 
are fully explained in the application.  There must be letters from the 
applicant and collaborating institutions that signify their intent to 
participate and to provide the necessary resources proposed in the 
application.  The minority-serving institution must allow the applicant a 
minimum 50% reserved time to devote to the specific aims of the proposed 
research during the academic year.  The collaborator must indicate in the 
application the percent effort that will be contributed to the proposed 
research project.  

o Before developing the application, the applicants should obtain a copy of 
the latest published policy governing consortia in the NIH Grants Policy 
Statement (3/01).  

o The NIAMS strategic plans for fiscal years 2000-2004 and for health 
disparities focus on a multidisciplinary approach to accomplish goals of " 
Healthy People 2010" as they relate to diseases that affect bones, joints, 
muscles, and skin.  Priority areas outlined in these strategic plans may be 
reviewed at http://www.niams.nih.gov/an/stratplan/index.htm .

MECHANISM OF SUPPORT

o This PA will use the NIH S11 award mechanism. Up to five years of support 
may be requested for a CAMSSA (S11).  The applicant and collaborating 
investigator will be solely responsible for planning, directing, and executing 
the proposed project. Awards are not renewable. 

o This PA uses just-in-time concepts.  The CAMSSA Program will not use the 
modular budget format. Detailed budget information should be submitted with 
the grant application.  Instructions for non-modular research grant 
applications may be reviewed at 
https://grants.nih.gov/grants/funding/phs398/phs398.html .  This program does 
not require cost sharing as defined in the current NIH Grants Policy Statement 
at https://grants.nih.gov/archive/grants/policy/nihgps_2001/part_i_1.htm.  

o Amount of Award: The NIAMS anticipates that the average CAMSSA will total 
approximately $200,000 per year in direct costs.  This is not meant to be a 
budget ceiling.  Funds may be requested to cover costs traditionally requested 
in a research grant.  Facilities and administrative (indirect) costs will be 
awarded based on the applicant institution's federally negotiated facilities 
and administrative cost rate.  The application may contain a subcontract for 
the collaborating investigator to cover specific shared resources and any 
dedicated effort to the collaboration.  The NIAMS support for this PA is 
contingent upon the availability of funds and the receipt of a sufficient 
number of meritorious applications.

ELIGIBLE INSTITUTIONS 

The applicant institution must be an institution with substantial minority 
enrollment that may be a non-Federal, public or private nonprofit institution 
located in the United States, its possessions or territories.  The 
collaborating institution must also be a non-Federal, public or private 
nonprofit institution located in the United States, its possessions or 
territories.

INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS 

Any full-time faculty member at a minority-serving institution who has the 
skills, knowledge, and resources necessary to develop and implement a research 
career in arthritis, musculoskeletal diseases or skin diseases related 
research is eligible to apply.  Women and individuals from underrepresented 
racial and ethnic groups, as well as individuals with disabilities are 
encouraged to apply for NIH programs.

SPECIAL REQUIREMENTS

The applicant investigator must have a doctoral degree in a basic or clinical 
science area.  The ideal applicant investigator should have completed one or 
more years of postdoctoral research experience and must be a full-time 
employee of the applicant institution.  The applicant investigator must be a 
citizen or non-citizen national of the United States or its possessions and 
territories, or must have been lawfully admitted to the United States for 
permanent residence at the time of application.  If the application is funded, 
permanent residents must submit at the time of award a notarized statement 
indicating that the candidate has an alien Registration Receipt Card, and that 
the form number of the card is either 1-551 or 1-151.

The collaborating investigator must be a grantee from a research-intensive 
institution who has current R01 or R01-level research support to conduct 
research in arthritis, musculoskeletal diseases or skin diseases.  
Racial/ethnic minority individuals, women, and persons with disabilities are 
encouraged to serve as collaborators.

Meetings should be held at the minority institution and the collaborating 
institution with a frequency that is conducive to accomplishing the proposed 
research.  A minimum of one meeting per year is required.  To facilitate 
maximum collaborative efforts, applicants are strongly encouraged to identify 
collaborators who are located within 100 miles of their minority-serving 
institution.  If the collaborator is geographically distant from the applicant 
institution, a detailed communication plan must be provided to document the 
collaborative relationship and level of commitment for the successful 
implementation and completion of the proposed research and career development 
program.

Annual progress reports should include a thorough description of 
accomplishments and setbacks during each fiscal year.  Contributions made to 
the proposed research on behalf of the principal investigator and the 
collaborator will be evaluated annually. Development of a successful 
collaboration will be one criterion for continued support. 

WHERE TO SEND INQUIRIES

We encourage your inquiries concerning this PA and welcome the opportunity to 
answer questions from potential applicants.  Inquiries may fall into three 
areas: scientific/research, peer review, and financial or grants management 
issues:  

o Direct questions about scientific/research issues to:

Charisee A. Lamar, Ph.D., M.P.H.
Program Director for Health Disparities and Women's Health Research 
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd., Suite 800
Bethesda, MD  20892-4872
Phone:  301-451-6514
Fax:  301-480-4543
Email:  lamarc@mail.nih.gov

o Direct your questions about peer review issues to:  

Teresa Nesbitt, D.V.M., Ph.D.
Chief, Review Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd, Suite 800
Bethesda, MD 20892-4872
Phone:   301-594-4952
Fax: 301-402-2406
  or 301-480-4543
Email: nesbittt@mail.nih.gov

o Direct your questions about financial or grants management matters to:

Melinda Nelson
Chief Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd., Suite 800
Bethesda, MD  20892-4872
Phone:  301-594-3535
Fax:  301-480-5450
Email:  nelsonm@mail.nih.gov

SUBMITTING AN APPLICATION 
 
Applications must be prepared using the PHS 398 research grant application 
instructions and forms (rev. 5/2001). Applications must have a DUN and 
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the 
Universal Identifier when applying for Federal grants or cooperative 
agreements. The DUNS number can be obtained by calling (866) 705-5711 or 
through the web site at http://www.dunandbradstreet.com/. The DUNS number 
should be entered on line 11 of the face page of the PHS 398 form. The PHS 398 
document is available at 
https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive 
format.  For further assistance contact GrantsInfo, Telephone (301) 710-0267, 
Email: GrantsInfo@nih.gov. 

The title and number of this PA must be typed in Item 2 of the face page of 
the application form and the YES box must be checked.
 
SUPPLEMENTARY INSTRUCTIONS

All instructions for the PHS 398 (rev. 5/2001) must be followed with this 
addition: The S11 mechanism is intended to promote productive research 
interactions between a minority-serving institution and a research intensive 
institution.  If the institutions are not in physical proximity, the distance 
puts an added burden on justifying the collaboration.  Therefore, the 
applicant must include a section in the research application appearing after 
the Specific Aims entitled: "Proposed Research Collaborations" to address the 
following issues:

a) The proposed plan to enhance communications, cooperation, and scientific 
collaboration among the participating investigators, as well as the potential 
for the collaborative research effort to develop and promote competitive 
NIAMS-related research at the predominantly minority institution.

b) The intellectual and physical environment in which the research would be 
conducted, taking into account the proposed activities at applicant's and 
collaborator's institutions.

c) Soundness of administrative support and organizational structure that 
facilitates the attainment of the objectives of the proposed research project.

The collaborating investigator should independently address these issues in 
the letter and the subcontract should be structured to reflect the 
interactions outlined.

APPLICATION RECEIPT DATES: Applications submitted in response to this program 
announcement will be accepted at the standard application deadlines, which are 
available at https://grants.nih.gov/grants/dates.htm.  Application deadlines 
are also indicated in the PHS 398 application kit.

SENDIING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of 
the application, including the checklist, and three signed photocopies in one 
package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)

In addition, two copies of the application and all five copies of the appendix 
material should be mailed to:

Teresa Nesbitt, D.V.M., Ph.D.
Chief, Review Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd., Suite 800
Bethesda, MD 20892-4872

APPLICATION PROCESSING: Applications must be mailed on or before the receipt 
dates described at 
https://grants.nih.gov/grants/funding/submissionschedule.htm. The CSR will 
not accept any application in response to this PA that is essentially the same 
as one currently pending initial review unless the applicant withdraws the 
pending application.  The CSR will not accept any application that is 
essentially the same as one already reviewed.  This does not preclude the 
submission of a substantial revision of an unfunded version of an application 
already reviewed, but such application must include an Introduction addressing 
the previous critique.  

Although there is no immediate acknowledgement of the receipt of an 
application, applicants are generally notified of the review and funding 
assignment within 8 weeks.

PEER REVIEW PROCESS

Upon receipt, applications will be reviewed for completeness by the CSR and 
responsiveness by the NIAMS. Incomplete and/or non-responsive applications 
will be returned to the applicant without further consideration. Applications 
that are complete and responsive to the PAR will be evaluated for scientific 
and technical merit by an appropriate peer review group convened by the NIAMS 
in accordance with the standard NIH peer review procedures. As part of the 
initial merit review, all applications will receive a written critique and 
undergo a process in which only those applications deemed to have the highest 
scientific merit, generally the top half of applications under review, will be 
discussed, assigned a priority score, and receive a second level review by the 
NIAMS advisory council.

REVIEW CRITERIA

The application must be sufficiently complete to allow an evaluation of the 
scientific objectives and proposed research plan.  Applications must 
adequately document the plans for efficacious collaborative interactions and 
the potential for achieving the scientific goals of the research and for 
developing a competitive NIAMS-relevant research program by the end of the 
funding period.

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments reviewers will be asked to discuss the following aspects 
of the application in order to judge the likelihood that the proposed research 
will have a substantial impact on the pursuit of these goals: 

o Significance 
o Approach 
o Innovation
o Investigator
o Environment

A review by a NIAMS Special Emphasis Panel will address and consider each of 
these criteria in assigning the application's overall score, weighting them as 
appropriate for each application.  The application does not need to be strong 
in all categories to be judged likely to have major scientific impact and thus 
deserve a high priority score.  For example, an investigator may propose to 
carry out important work that by its nature is not innovative but is essential 
to move a field forward.

SIGNIFICANCE:  Does this study address an important problem?  If the aims of 
the application are achieved, how will scientific knowledge be advanced?  What 
will be the effect of these studies on the concepts or methods that drive this 
field?

APPROACH:  Are the conceptual framework, design, methods, and analyses 
adequately developed, well integrated, and appropriate to the aims of the 
project?  Does the applicant acknowledge potential problem areas and consider 
alternative tactics?

INNOVATION:  Does the project employ novel concepts, approaches or method? Are 
the aims original and innovative?  Does the project challenge existing 
paradigms or develop new methodologies or technologies?

INVESTIGATOR:  Is the investigator appropriately trained and well suited to 
carry out this work?  Is the work proposed appropriate to the experience level 
of the principal investigator and other researchers?

ENVIRONMENT:  Does the scientific environment in which the work will be done 
contribute to the probability of success?  Do the proposed experiments take 
advantage of unique features of the scientific environment or employ useful 
collaborative arrangements?  Is there evidence of institutional support?

ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, in accordance 
with NIH policy, all applications will also be reviewed with respect to the 
following:

PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human 
subjects and protections from research risk relating to their participation in 
the proposed research will be assessed. (See criteria included in the section 
on Federal Citations, below). 
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm 

INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans 
to include subjects from both genders, all racial and ethnic groups (and 
subgroups), and children as appropriate for the scientific goals of the 
research will be assessed.  Plans for the recruitment and retention of 
subjects will also be evaluated. (See Inclusion Criteria in the section on 
Federal Citations, below).

CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to 
be used in the project, the five items described under Section f of the PHS 
398 research grant application instructions (rev. 5/2001) will be assessed.  

ADDITIONAL REVIEW CONSIDERATIONS

BUDGET: The reasonableness of the proposed budget and duration in relation to 
the proposed research.

ADDITIONAL SCIENTIFIC/TECHNICAL MERIT CRITERIA SPECIFIC TO THE OBJECTIVES OF 
THIS CAMSSA PA ARE:

a) The proposed plan to enhance communications, cooperation, and scientific 
collaboration among the participating investigators, as well as the potential 
for the collaborative research effort to develop and promote competitive 
NIAMS-related research at the predominantly minority-serving institution.

b) The intellectual and physical environment in which the research would be 
conducted, taking into account the proposed activities at applicant's and 
collaborator's institutions.

c) Soundness of administrative support and organizational structure that 
facilitates the attainment of the objectives of the proposed research project.

AWARD CRITERIA

Award criteria that will be used to make award decisions include:

o   Scientific merit as determined by peer review
o   Availability of funds
o   Relevance to program priorities

Applications will compete for available funds with all other recommended 
applications. The following will be considered in making funding decisions: 
Quality of the proposed project as determined by peer review, availability of 
funds, and program priority.
 
REQUIRED FEDERAL CITATIONS 

HUMAN SUBJECTS PROTECTION:  Federal regulations (45CFR46) require that 
applications and proposals involving human subjects must be evaluated with 
reference to the risks to the subjects, the adequacy of protection against 
these risks, the potential benefits of the research to the subjects and 
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm 

DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required for 
all types of clinical trials, including physiologic, toxicity, and dose-
finding studies (phase I); efficacy studies (phase II), efficacy, 
effectiveness and comparative trials (phase III). The establishment of data 
and safety monitoring boards (DSMBs) is required for multi-site clinical 
trials involving interventions that entail potential risk to the participants. 
(NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and 
Contracts, June 12, 1998: 
https://grants.nih.gov/grants/guide/notice-files/not98-084.html).  
 
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of 
the NIH that women and members of minority groups and their sub-populations 
must be included in all NIH-supported clinical research projects unless a 
clear and compelling justification is provided indicating that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of the 
research. This policy results from the NIH Revitalization Act of 1993 (Section 
492B of Public Law 103-43).

All investigators proposing clinical research should read the "NIH Guidelines 
for Inclusion of Women and Minorities as Subjects in Clinical Research - 
Amended, October, 2001," published in the NIH Guide for Grants and Contracts 
on October 9, 2001 
(https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); 
the updated Guidelines are available at 
https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical 
research; updated racial and ethnic categories in compliance with the new OMB 
standards; clarification of language governing NIH-defined Phase III clinical 
trials consistent with the new PHS Form 398; and updated roles and 
responsibilities of NIH staff and the extramural community.  The policy 
continues to require for all NIH-defined Phase III clinical trials that: a) 
all applications or proposals and/or protocols must provide a description of 
plans to conduct analyses, as appropriate, to address differences by 
sex/gender and/or racial/ethnic groups, including subgroups if applicable; 
and b) investigators must report annual accrual and progress in conducting 
analyses, as appropriate, by sex/gender and/or racial/ethnic group 
differences.

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS: 
The NIH maintains a policy that children (i.e., individuals under the age of 
21) must be included in all human subjects research, conducted or supported 
by the NIH, unless there are scientific and ethical reasons not to include 
them. This policy applies to all initial (Type 1) applications submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the inclusion of children as participants in 
research involving human subjects that is available at 
https://grants.nih.gov/grants/funding/children/children.htm. 

REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH 
policy requires education on the protection of human subject participants for 
all investigators submitting NIH proposals for research involving human 
subjects.  You will find this policy announcement in the NIH Guide for Grants 
and Contracts Announcement, dated June 5, 2000, at 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

HUMAN EMBRYONIC STEM CELLS (hESC):  Criteria for federal funding of research 
on hESCs can be found at http://stemcells.nih.gov/index.asp and at 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.  Only 
research using hESC lines that are registered in the NIH Human Embryonic Stem 
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov). 
It is the responsibility of the applicant to provide, in the project 
description and elsewhere in the application as appropriate, the official NIH 
identifier(s) for the hESC line(s) to be used in the proposed research.  
Applications that do not provide this information will be returned without 
review. 

PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The 
Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) 
cited publicly and officially by a Federal agency in support of an action 
that has the force and effect of law (i.e., a regulation) may be accessed 
through FOIA.  It is important for applicants to understand the basic scope 
of this amendment.  NIH has provided guidance at 
https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.

Applicants may wish to place data collected under this PA in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time.  If so, the application should 
include a description of the archiving plan in the study design and include 
information about this in the budget justification section of the 
application. In addition, applicants should think about how to structure 
informed consent statements and other human subjects procedures given the 
potential for wider use of data collected under this award.

STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The 
Department of Health and Human Services (DHHS) issued final modification to 
the "Standards for Privacy of Individually Identifiable Health Information", 
the "Privacy Rule," on August 14, 2002.  The Privacy Rule is a federal 
regulation under the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 that governs the protection of individually identifiable 
health information, and is administered and enforced by the DHHS Office for 
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified 
under the Rule as "covered entities") must do so by April 14, 2003  (with the 
exception of small health plans which have an extra year to comply).  

Decisions about applicability and implementation of the Privacy Rule reside 
with the researcher and his/her institution. The OCR website 
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including 
a complete Regulation Text and a set of decision tools on "Am I a covered 
entity?"  Information on the impact of the HIPAA Privacy Rule on NIH processes 
involving the review, funding, and progress monitoring of grants, cooperative 
agreements, and research contracts can be found at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.

URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals 
for NIH funding must be self-contained within specified page limitations. 
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) 
should not be used to provide information necessary to the review because 
reviewers are under no obligation to view the Internet sites.   Furthermore, 
we caution reviewers that their anonymity may be compromised when they 
directly access an Internet site.

HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to 
achieving the health promotion and disease prevention objectives of "Healthy 
People 2010," a PHS-led national activity for setting priority areas. This PA 
is related to one or more of the priority areas. Potential applicants may 
obtain a copy of "Healthy People 2010" at http://www.healthypeople.gov/.

AUTHORITY AND REGULATIONS: This program is described in the Catalog of Federal 
Domestic Assistance at http://www.cfda.gov/ and is not subject to the 
intergovernmental review requirements of Executive Order 12372 or Health 
Systems Agency review.  Awards are made under the authorization of Sections 
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) 
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92.  All 
awards are subject to the terms and conditions, cost principles, and other 
considerations described in the NIH Grants Policy Statement.  The NIH Grants 
Policy Statement can be found at 
https://grants.nih.gov/grants/policy/policy.htm 

The PHS strongly encourages all grant recipients to provide a smoke-free 
workplace and discourages the use of all tobacco products.  In addition, 
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
facilities (or in some cases, any portion of a facility) in which regular or 
routine education, library, day care, health care, or early childhood 
development services are provided to children.  This is consistent with the 
PHS mission to protect and advance the physical and mental health of the 
American people.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.